Table 1 Comparison of viability and spheroid formation for the three culture conditions tested in this paper

From: A microfluidic platform for cultivating ovarian cancer spheroids and testing their responses to chemotherapies

PDX models

Histotype

Viability (%) at day 14

Spheroids Size (fold increase) at day 14

Matrigel

Standard

Microfluidic

Standard

Microfluidic

PH039

Serous

65 ± 16.5a

66 ± 8.3a

87 ± 8.0

1.3 ± 0.14a

1.7 ± 0.24

PH063

Serous

86 ± 4.8a

61 ± 3.6a

95 ± 2.4

1.1 ± 0.08a

1.6 ± 0.18

PH592

MMMT

83 ± 5.0a

60 ± 11.9a

88 ± 3.7

1.1 ± 0.11a

1.8 ± 0.16

PH704

Serous

82 ± 6.6 N.S.

58 ± 5.1a

86 ± 2.7

1.1 ± 0.12a

1.3 ± 0.13

PH757

Serous

84 ± 1.3a

66 ± 15.2a

99 ± 0.3

1.7 ± 0.42a

2.5 ± 0.19

PH938

Serous

85 ± 8.7a

79 ± 12.9a

96 ± 1.6

1.3 ± 0.11a

1.6 ± 0.14

  1. aSignificantly lower (p < 0.05) compared to the values from the microfluidic culture format (n = 6)
  2. NS Not significant difference (p < 0.05) compared to the values from the microfluidic device (n = 6)